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A B S T R A C T
Purpose: The pathomechanism and treatment of PCDH19 female epilepsy (PCDH19-FE) remain unclear.
Here, we report that corticosteroids are effective for control of the seizure clusters or other acute
symptoms of PCDH19-FE and argue for the possible involvement of a compromised blood-brain barrier
(BBB) in its pathogenesis.
Methods: The efﬁcacy of corticosteroids was retrospectively reviewed in ﬁve Japanese patients with
PCDH19-FE. The results of antibody assays against the N-methyl-D-aspartate-type glutamate receptor
(abs-NR) in serum/cerebrospinal ﬂuid were also compiled.
Results: Corticosteroid treatments signiﬁcantly improved the acute symptoms, including seizure
clusters, in all cases, most often immediately after the initial administration. However, the effect was
transient, and some seizures recurred within a few weeks, especially in association with fever. Serum
and/or cerebrospinal ﬂuid abs-NR were detected in all patients. Target sequences of the detected
antibodies were multiple, and the titers tended to decrease over time. In one patient, immunohisto-
chemical analysis using rat hippocampal slices also revealed serum antibodies targeting an unknown
epitope in neuronal cytoplasm.
Conclusion: Our ﬁndings imply an involvement of inﬂammatory processes in the pathogenesis of
PCDH19-FE and therapeutic utility for corticosteroids as an adjunctive option in acute treatment. PCDH19
is well expressed in brain microvascular endothelial cells and thus its impairment may cause BBB
vulnerability, which may be ameliorated by corticosteroids. The abs-NR detected in our patients may not
indicate an autoimmune pathomechanism, but may rather represent non-speciﬁc sensitization to
degraded neuronal components entering the general circulation, the latter process facilitated by the BBB
vulnerability.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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A heterozygous defect in the gene encoding protocadherin 19
(PCDH19) causes early-onset intractable epilepsy in females (i.e.,
PCDH19-related female epilepsy, PCDH19-FE, or previously,
epilepsy and mental retardation limited to females, EFMR)
[1]. PCHD19, an adhesion molecule of the d2-protocadherin
subclass of the cadherin superfamily, is highly expressed in the
vertebrate brain. d-Protocadherins are intimately involved in
brain development and neural functions, as well as in many
neurological diseases [2]. However, the homophilic adhesion
capacity of PCDH19 by itself is low, and its exact function remains
unclear.
The hallmark clinical feature of PCDH19-FE is recurrent seizure
clusters consisting of brief focal seizures and/or generalized
convulsions, which can be triggered by febrile or afebrile illnesses
[3]. The seizures do not recur regularly, but once they recur, the
cluster continues for days to weeks despite multiple treatments.
Conventional antiepileptic drugs fail to control or prevent most of
these seizures. Ictal symptoms and EEG ﬁndings indicate that the
seizures mainly involve the limbic system and medial frontal
region [4].
The clinical features indicate a possible immune/inﬂammation
involvement in seizure generation, which could be a non-genetic
modiﬁer of the disease phenotype. In agreement with this, we have
previously reported patients showing excellent efﬁcacy of corti-
costeroids for seizure clusters [5]. We have also encountered cases
having antibodies to the N-methyl-D-aspartate (NMDA)-type
glutamate receptor (abs-NR) in the serum or cerebrospinal ﬂuid
(CSF). Abs-NR cause limbic encephalitis, predominantly in young
women (anti-NMDA receptor encephalitis) [6], but may also
appear secondarily and non-speciﬁcally in various neurologic
diseases including epilepsy [7]. In the latter case, abs-NR are not
signiﬁcantly involved in the disease pathogenesis.
This study aims to explore whether corticosteroids have an
ability to improve the seizures in PCDH19-FE and if any immune
mechanism is involved. We retrospectively reviewed and summa-
rized the clinical results of corticosteroid treatments as well as the
results of an assay for abs-NR in Japanese patients. The potential
signiﬁcance of these ﬁndings with regard to the pathomechanisms
of this disorder is also discussed.
2. Methods
2.1. Patients
Japanese patients with PCDH19-FE who received corticosteroid
treatments and/or underwent the ab-NR assay were retrospec-
tively studied. They were genetically diagnosed at Fukuoka
University5 and clinical details were collected from their doctors
in charge. Since the patients were children, the doctors obtained
written informed consent from the parents before the blood and/or
CSF samples were drawn for genetic analysis of PCDH19 and/or for
assay for ab-NR. Genetic analysis of PCDH19 was approved by the
ethics committee of Fukuoka University. The ab-NR assay was
approved by the National Epilepsy Center, Shizuoka Institute of
Epilepsy and Neurological Disorders.
2.2. ab-NR assay
The ab-NR assay was performed at National Epilepsy Center,
Shizuoka Institute of Epilepsy and Neurological Disorders.
Experimental details have been described elsewhere [8]. Brieﬂy,
serum and CSF samples were examined by enzyme-linked
immunosorbent assay (ELISA) or, in one patient, by immunoblotanalysis targeting GluN2B. The ELISA target peptides were the
extracellular N-terminal (NT) and/or intracellular C-terminal (CT)
regions of the GluN2B, GluN1, and GluD2 subunits (Supplementary
Table 1). Titers were determined by comparing the optical
densities of our patients with those of 35 patients with non-
inﬂammatory focal epilepsy, who served as controls. The results
were expressed as number of standard deviations of the controls
(SD) from the mean of the controls and were considered positive
when 2 SD.
2.3. Immunohistochemical analysis for anti-neuronal autoantibodies
In two patients, the presence of anti-neuronal autoantibodies
was further examined immunohistochemically using rat hippo-
campal slices exposed to serum or CSF from the patients.
Experimental details are described in Supplementary information.
3. Results
Five patients (Patients 1–5) received corticosteroid treatments
mainly during the acute phase before and/or after the diagnosis of
PCDH19-FE. Abs-NR were examined in these patients mostly before
corticosteroid administration and in four other patients (Patients
6–9). These tests were performed because autoimmune or
inﬂammatory processes were clinically suspected in the patho-
genesis of the epilepsy, although none of these patients except
Patient 4 showed pleocytosis or an elevation of CSF protein level.
Outlines of Patients 1, 2, and 5–9 have been described previously
[3,5].
3.1. Efﬁcacy of corticosteroid treatments
Treatment details and results are summarized in Table 1. The
details of the clinical courses are described in Supplementary
information. Overall, corticosteroids dramatically improved acute
neurological symptoms: ongoing seizure clusters in Patients 1–3
and 5, and an acute encephalopathic episode that developed after a
seizure cluster in Patient 4, were controlled. In most cases, the
improvement was achieved after the ﬁrst administration. In the
cases of seizure cluster, the initial administration was conducted
well in advance of the expected time of spontaneous remission of
the cluster. Furthermore, in Patient 3, corticosteroids were
initiated on the second day of each cluster to conﬁrm that the
cluster continued for more than 1 day despite midazolam
administration. Regarding drugs and dosages, four young patients
(Patients 1–4) received an intravenous drip infusion of 10–30 mg/
kg methylprednisolone once daily, for up to 3 days. Patient
5 received an intravenous infusion of 0.35 mg/kg prednisolone
once or twice, depending on the cluster, followed by oral
administration of prednisolone at 1 mg/(kgday) at age 11. Howev-
er, as observed in Patients 1, 3, and 5, the effect was fundamentally
transient; seizure clusters often recurred within a few weeks,
especially when fever appeared.
For Patient 4, methylprednisolone was used at age 1 for an
encephalopathic episode with decline of consciousness and
systemic weakness, which abruptly developed 3 days after the
termination of a one-day seizure cluster. EEG showed an increase
of d-waves, but no ictal activity. Mild CSF pleocytosis (85 cells/mL)
was identiﬁed a week before the episode. These symptoms
completely disappeared immediately after the initial administra-
tion of methylprednisolone.
For Patient 1, corticosteroids were administered prophylacti-
cally after age 3, with 3 days of oral betamethasone or prednisolone
administration at times of fever appearance. After starting this
treatment, no or only mild recurrences (not requiring hospitaliza-
tion) were observed, even during fever.
Table 1
Details and efﬁcacy of corticosteroid therapy.
Pt no PCDH19
mutation
Age at
onset (m)
Age at
CS TX
CS Route & dose Target
symptom
Simultaneous
TX
Usual duration
of Sz cluster
Result Present
intellect
1 p.L719* 13 2y4m mPSL IV, 30 mg/kg, 3d Sz cluster MDL CBZ CZP
VPA LTG LEV
Days 2 wk Disappeared after
1st IV
Normal
5y1m
2y10m mPSL IV, 30 mg/kg, 3d Sz cluster Disappeared after
1st IV
Recurred in
2 wk w/fevera
2y11m mPSL IV, 30 mg/kg, 3d Sz cluster Disappeared after
1st IV
Recurred in
1wk w/fever
3y0m mPSL IV, 10 mg/kg, 3d Sz cluster Disappeared after
1st IV
3y4m BET Oral, 0.01 mg/kg, 3d
When fever appeared
Sz prevention No or mild
recurrence
4y1m PSL Oral, 1–1.5 mg/kg, 3d
When fever appeared
Sz prevention No or mild
recurrence
2 p.K120Rfs*3 10 10m mPSL IV, 30 mg/kg, 3d Sz cluster MDL PB ACV
IVIG EDV
– Disappeared after
1st IV
Recurred in 1wk
Moderate
delay 3y
3 p.D417H
p.D596Y
5 1y11m mPSL IV, 20 mg/kg, 2d Sz cluster MDL fPHT CLB
LEV KBr DZP
Days 2wk Disappeared after
1st IV
Normal
2y8m
2y1m mPSL IV, 20 mg/kg, 3d Sz cluster Disappeared after
1st IV
2y2m mPSL IV, 20 mg/kg, 2d Sz cluster Disappeared after
1st IV
2y5m mPSL IV, 10 mg/kg, 1d
fol. by 20 mg/kg, 1d
Sz cluster Disappeared after
2nd IV
2y7m mPSL IV, 20 mg/kg, 1d Sz cluster Disappeared after
1st IV
Recurred in
9d w/ﬂu
2y7m mPSL IV, 20 mg/kg, 2d Sz cluster Disappeared after
1st IV
4 p.D596G 6 1y0m mPSL IV, 30 mg/kg, 3d Encephalopatic
symptoms
CBZ fPHT LDC
PB
1d Disappeared after
1st IV
Hyperactive
1y6m
5 p.D45Gfs*43 8 11y5m PSL IV, 0.35 mg/kg x1
fol. by Oral, 1 mg/kgb
Sz cluster KBr CZP Half a day Disappeared after
1st IV
Moderate
delay
11y8m11y6m PSL IV, 0.35 mg/kg x1
fol. by Oral, 1 mg/kg
Sz cluster Disappeared after
1st IV
Recurred in
1wk w/fever
11y6m PSL IV, 0.35 mg/kg x1
fol. by Oral, 1 mg/kg
Sz cluster Disappeared after
1st IV
11y8m PSL IV, 0.35 mg/kg x2
fol. by Oral, 1 mg/kg
Sz cluster Disappeared after
2nd IV
a Noted when seizures recurred within 3 weeks after corticosteroid administration.
b In Patient 5, oral prednisolone was gradually tapered off. Pt no, Patient number; m, month(s); CS, corticosteroid; TX, treatment; Sz, seizure; y, year(s); mPSL,
methylprednisolone; BET, betamethasone; PSL, prednisolone; IV, intravenous route; d, day(s); MDL, midazolam; CBZ, carbamazepine; CZP, clonazepam; VPA, valproic acid;
LTG, lamotrigine; LEV, levetiracetam; wk, week(s); PB, phenobarbital; ACV, acyclovir; IVIG, intravenous immunoglobulin; EDV, edaravone; fol. by, followed by; fPHT,
fosphenytoin; CLB, clobazam; KBr, potassium bromide; DZP, diazepam; LDC, lidocaine.
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Eight of the nine patients who underwent the assay showed
positivity to multiple epitopes in the serum or CSF (Patients 1–7
and 9, 88.9%, Table 2). The epitopes included GluN1-NT, which has
been reported to be critical for the emergence of neuropsychiatric
symptoms in anti-NMDA-receptor encephalitis [6]. Patients 1 and
2 had high CSF titers of antibodies during the acute phase (>10
SD). Patient 6 showed positivity in the CSF at onset and in serum
half a year later. Patients 3, 5, and 9 underwent follow-up assays,
and their titers were found to decrease over time. In Patient 5,
immunohistochemical analysis during seizure recurrence at
age 11, using serum drawn before prednisolone administration,
revealed autoantibodies to the cytoplasm of hippocampal
neurons, as demonstrated in hippocampal slices taken from rats(Supplementary Fig. b). The assay failed to identify the epitope.
These results suggest that following seizure clusters, an immune
reaction occurs non-speciﬁcally to degraded neuronal proteins,
including NMDA-type glutamate receptor, inside and subsequent-
ly outside the brain. Such reactions appear to be strong at early
ages, but do not show a uniform pattern.
4. Discussion
This study revealed the therapeutic potency of corticosteroids
for acute symptoms in PCDH19-FE. The rapid and efﬁcient response
was remarkable and might be a useful indicator for this disease.
The cases of Patients 1 and 9 suggested that oral corticosteroids
taken during interictal periods might exert some prophylactic
effects, but further assessments are necessary to establish this.
Table 2
Results of assay for antibodies to N-methyl-D-aspartate-type glutamate receptor.
Pt no PCDH19
mutation
Age at
onset (m)
Age at
assay
Serum Cerebrospinal ﬂuid
GluN2B GluN1 GluD2 GluN2B GluN1 GluD2
NT CT NT NT CT NT CT NT NT CT
1 p.L719* 13 2y5m 1.61 3.12 1.93 0.45 14.10 15.10 10.80 8.10
2 p.K120Rfs*3 10 11m 15.42
4y2m 2.21 1.53 3.58 3.63
3 p.D417H
p.D596Y
Heterozygous
5 11m 2.17 2.94 3.62 2.85
1y0m 3.39 3.28 2.81 2.35
1y7m 2.65 2.21 2.17 1.95
1y10m 1.23 0.37 0.72 0.99
4 p.D596G 6 1y0m 2.67 2.39 1.51 1.68
5 p.D45Gfs*43 8 9m +  +
3y5m  
6 Whole del 10 11m 0.57 1.70 0.46 (0.34) 1.61 2.73 1.34 0.75
1y5m 2.33 2.73 2.48 0.92 0.46 1.18 1.13 0.70
7 p.Asn340Ser 9 8y1m 3.49 2.07 9.55 1.87
8 p.R198L 7 6y5m 1.70 0.90 1.78 1.68
9 p.Y366Lfs*10 5 6y0m 9.52 12.50 9.20 0.88 1.37 1.08
8y5m 0.60 (0.35) 0.25 0.37
Results are expressed as standard deviation (SD, enzyme-linked immunosorbent assay) or plus/minus sign (immunoblot, Patient 5 only). Bold values denote positivity (2 SD
or +). Blanks are unexamined. *Patients who received corticosteroid treatments. Pt no, Patient number; m, month(s); NT, N-terminal; CT, C-terminal; y, year(s); Whole del,
Whole PCDH19 deletion.
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provided only transient effects and had no potential for preventing
further seizure clusters. Therefore, the clinical beneﬁt will be
limited for cases with frequent recurrences such as Patients 3 and
5. Moreover, excessive amounts of corticosteroids may have
adverse effects, actually increasing seizure-proneness as described
below. These ﬁndings suggest that the attending physician should
consider discontinuing corticosteroid administration for acute
treatment soon after seizure disappearance. Indication for
treatment should be based on various patient conditions such as
age, seizure severity, and comorbid infections.
Corticosteroids may exert primarily excitatory/pro-convulsive
actions on brain neurons both in vitro and in vivo, especially under
chronic stress conditions such as epilepsy [9]. Despite this, the
therapeutic efﬁcacy of corticosteroids is well established in many
intractable epilepsies such as West syndrome, Landau-Kleffner
syndrome, and autoimmune epilepsy/encephalitis [10]. In these
diseases, clinical improvements after corticosteroid administra-
tion are usually delayed and are probably mediated by mecha-
nisms such as immunosuppression and feedback inhibition of
corticotropin-releasing hormone secretion. In our patients, how-
ever, the clinical effects appeared quickly, usually immediately
after the initial administration. Moreover, signiﬁcant brain
inﬂammation was not found, suggesting a particular pathogenesis
and mechanism of action of corticosteroids in PCDH19-FE.
Such a mechanism may be restoration of blood-brain barrier
(BBB) integrity [11]. This is known to be a crucial action of
corticosteroids, the underlying molecular basis of which has been
partially elucidated [12]. Seizures are easily triggered by a mild
breakdown of brain homeostasis due to a compromised BBB, which
can be prevented or alleviated by corticosteroid administration
[13]. Although PCDH19 is abundantly expressed in brain neurons,
it is unclear how the heterozygous mutation in PCDH19 leads to
epilepsy in females. ‘‘Cellular interference,’’ that is, the presence of
somatic mosaicism in PCDH19 expression between normal and
abnormal neurons, is the currently proposed explanation for such
sex-speciﬁc pathogenesis, but the concept is very theoretical andhas yet to be established. However, PCDH19 is also expressed in the
BBB. In mouse, the BBB-speciﬁc transcriptome included PCDH19,
and PCDH19 expression in microvascular endothelial cells was
signiﬁcantly higher in the brain than in the liver or lung
[14]. Although currently no human evidence exists, this study
suggests that PCDH19 plays a role in the BBB, and speculatively,
that PCDH19 mutation leads to a functional BBB vulnerability, that
underlies the pathogenesis of PCDH19-FE.
Interestingly, PCDH19 expression may be signiﬁcantly altered in
the BBB during systemic inﬂammation, which is the predisposing
factor for seizure recurrence in PCDH19-FE. In cultured mouse brain
microvascular endothelial cells, treatment with lupus serum or an
activated complement, C5a, signiﬁcantly down-regulated miR-320a
expression [15]. PCDH19 is one potential target of this microRNA.
Although systemic inﬂammation will impair BBB function to some
extent [16], the impairment may be exacerbated in patients with
PCDH19-FE, probably due to PCDH19 insufﬁciency. The resulting
seizure clusters will further exacerbate the BBB dysfunction by
inducing brain inﬂammation. Corticosteroids may ameliorate such
dysfunction and thus the acute neurological symptoms.
Other aspects of PCDH19-FE and the ﬁndings of this study are
also consistent with the BBB hypothesis: The seizures mainly
involve the limbic system, which is anatomically close to some of
the periventricular regions that lack a BBB due to their endocrine
roles; seizure occurrence and remission are strongly age-related,
and BBB integrity also develops age-dependently; abs-NR in our
patients covered multiple epitopes of various subunits, and Patient
8 had antibodies to some neuronal cytoplasmic component(s) as
well. These results indicate that anti-neuronal antibodies may be
produced in PCDH19-FE non-speciﬁcally and commonly. Various
neuronal proteins will be degraded by recurrent seizures and the
compromised BBB may then facilitate leakage of such degraded
proteins into the bloodstream. This may induce non-speciﬁc
sensitization to them outside the brain, resulting in the high rate of
anti-neuronal autoantibody positivity seen in our patients. Thus,
the abs-NR found in our patients does not represent an
autoimmune pathogenesis.
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neurological phenotype in our patients with PCDH19-FE can also be
considered. The seroprevalence of abs-NR has been found to be
identical between patients with psychiatric diseases, including
schizophrenia, and healthy individuals, but the disease phenotypes
were more severe in patients with compromised BBBs than in
those without [17]. Serum abs-NR could have passed the
compromised BBB and worsened the psychiatric symptoms of
these patients. In anti-NMDA-receptor encephalitis, a primary
involvement of antibodies to GluN1-NT in causing its neuropsy-
chiatric symptoms has been suggested [6]. Therefore if BBB
compromise exists in PCDH19-FE, the anti-GluN1-NT could be
partially responsible for the neuropsychiatric symptoms also seen
in this disease.
This study proposes corticosteroid treatment as an efﬁcacious
adjunctive treatment for the acute symptoms of PCDH19-FE and
suggests BBB involvement in this disease. Although PCDH19-FE is
rare, future multicenter clinical trials should be conducted to verify
the acute and long-term efﬁcacy of corticosteroid treatment and to
deﬁne the therapeutic indications of such treatment, since the
present study is only a retrospective review of 5 patients. In
addition, reliable animal models should be devised to elucidate the
entire molecular pathogenesis of PCDH19-FE. Importantly, not only
must neurons be studied, but also other actors such as the BBB and
the inﬂammatory system as well.
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